Aura Biosciences/$AURA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Aura Biosciences

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Ticker

$AURA
Sector
Primary listing

Employees

-

Aura Biosciences Metrics

BasicAdvanced
$368M
-
-$1.95
0.46
-

What the Analysts think about Aura Biosciences

Analyst ratings (Buy, Hold, Sell) for Aura Biosciences stock.

Bulls say / Bears say

Bel-sar is in a global Phase III CoMpass trial for first-line treatment of early-stage choroidal melanoma, positioning AURA to potentially capture a vision-sparing therapy market earlier in disease progression (Financial Times)
Orphan and Fast Track designations for bel-sar should expedite development and grant market exclusivity, supported by orphan drugs commanding high returns and regulatory incentives such as 7-year US and 10-year EU exclusivity (Financial Times)
The company’s virus-like particle (VLP) platform allows conjugation with cytotoxic payloads or nucleic acids, enabling a versatile therapeutic pipeline targeting multiple solid tumors beyond ocular oncology, underpinning future growth prospects (Financial Times)
Dependence on a single late-stage asset bel-sar exposes AURA to binary risk; any setback in the Phase III CoMpass trial could severely impair valuation due to lack of alternative revenue drivers (Bloomberg)
AURA reported zero revenue (TTM) and a net loss of $101.38 million, indicating significant cash burn and likely need for dilutive funding absent near-term approvals, pressuring share value (Financial Times)
Orphan drugs face stringent pricing and reimbursement scrutiny, with bodies like NICE rejecting treatments costing over £100,000 per QALY, potentially limiting bel-sar’s commercial uptake in key European markets (Financial Times)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.

Aura Biosciences Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Aura Biosciences Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AURA

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs